Loading patent…
AssigneeKarolinska Innovations AB
InventorsMats Axel Atterdag Persson, Tobias Erik Allander
Estimating the term…
The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.
An isolated nucleic acid molecule encoding a human Fab molecule, wherein the nucleic acid molecule comprises:
An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a γ1 heavy chain variable region (VH) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than 1×107 M−1 for a hepatitis C virus (HCV) E2 antigen and further wherein the γ1 heavy chain sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.
An isolated nucleic acid molecule, comprising a first nucleotide sequence encoding a binding portion of a κ light chain variable region (VL) of a human Fab molecule obtained from a combinatorial library, wherein said Fab molecule exhibits immunological binding affinity greater than 1×107 M−1 for a hepatitis C virus (HCV) E2 antigen and further wherein the κ light chain sequence is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ED NO:10, SEQ ID NO:11, SEQ ID NO:
An isolated nucleic acid molecule that encodes a recombinant human monoclonal antibody that exhibits immunological binding affinity for a hepatitis C virus (HCV) E2 antigen, wherein the antibody comprises at least one group of three complementarity determining regions (CDRs) interposed between framework regions (FRs) said FRs derived from a human immunoglobulin, wherein the group of three CDRs is selected from the group consisting of amino acid residue numbers 32-36, 51-71, 104-121 of SEQ ID NO:1;
An isolated nucleic acid molecule encoding a human Fab molecule, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27.
Dependencies are inferred from the claim text.